ISDA

Entry Detail

PDB ID:

7UOQ

Keywords:

Title:

CRYSTAL STRUCTURE OF HIV-1 INTEGRASE COMPLEXED WITH (2S)-2-(TERT-BUTOXY)-2-(5-{2-[(2-CHLORO-6-M ETHYLPHENYL)METHYL]-1,2,3,4-TETRAHYDROISOQUINOLIN-6-YL}-4- (4,4-DIMETHYLPIPERIDIN-1-YL)-2-METHYLPYRIDIN-3-YL)ACETIC ACID

Biological Source:

Source Organism:

Human immunodeficiency virus 1

Host Organism:

Escherichia coli BL21

PDB Version:

Deposition Date:

2022-04-13

Release Date:

2022-07-06

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

1.89 Å

R-Value Free:

0.22

R-Value Work:

0.18

R-Value Observed:

0.18

Space Group:

P 31 2 1

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Description:Integrase
Mutations:C56S, F139D, F185H
Chain IDs:A
Chain Length:180
Number of Molecules:1
Biological Source:Human immunodeficiency virus 1

UniProt ID:P12497 Pfam ID:PF00665

Ligand Molecules

O20

SO4

Primary Citation

Discovery and Preclinical Profiling of GSK3839919, a Potent HIV-1 Allosteric Integrase Inhibitor.

Parcella, K, Wang, T, Eastman, K, Zhang, Z, Yin, Z, Patel, M, Tu, Y, Zheng, B.Z, Walker, M.A, Saulnier, M.G, Frennesson, D, Bowsher, M, Gillis, E, Peese, K, Belema, M, Cianci, C, Dicker, I.B, McAuliffe, B, Ding, B, Falk, P, Simmermacher, J, Parker, D.D, Sivaprakasam, P, Kish, K, Lewis, H, Hanumegowda, U, Jenkins, S, Kadow, J.F, Krystal, M, Meanwell, N.A, Naidu, B.N.Show

Acs Med.Chem.Lett. 13 972 980 (2022)

PMID: 35707159 DOI: 10.1021/acsmedchemlett.2c00115

Abstact

Allosteric HIV-1 integrase inhibitors (ALLINIs) have been of interest recently because of their novel mechanism of action. Strategic modifications to the C5 moiety of a class of 4-(4,4-dimethylpiperidinyl)-2,6-dimethylpyridinyl ALLINIs led to the identification of a tetrahydroisoquinoline heterocycle as a suitable spacer element to project the distal hydrophobic aryl ring. Subsequent optimization of the aryl substitutions identified 12 as an ALLINI with single-digit nanomolar inhibitory potency and low clearance across preclinical species. In preclinical toxicology studies with 12 in rats, lipid hepatocellular vacuolation was observed. Removal of the C6 methyl group resulted in GSK3839919 (22), which exhibited a reduced incidence and severity of lipid vacuolation in both in vitro assays and in vivo studies while maintaining the potency and pharmacokinetic (PK) properties of the prototype. The virology, PK, and toxicology profiles of 22 are discussed.

Legend

Protein

Chemical

Disease

Primary Citation of related structures